tetano
Editor, Senior Moderator
J Genet Genomics
. 2023 Oct 19:S1673-8527(23)00211-4.
doi: 10.1016/j.jgg.2023.10.003. Online ahead of print. Humoral and cellular immunity against diverse SARS-CoV-2 variants
Changxu Chen[SUP] 1 [/SUP], Xin Wang[SUP] 1 [/SUP], Zeli Zhang[SUP] 2 [/SUP]
Affiliations
Since the outbreak of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in late 2019, the virus has rapidly spread worldwide. This has led to an unprecedented global pandemic, marked by millions of COVID-19 cases and a significant number of fatalities. Over a relatively short period, several different vaccine platforms were developed and deployed for use globally to curb the pandemic. However, the genome of SARS-CoV-2 continuously undergoes mutation and/or recombination, resulting in the emergence of several variants of concern (VOC). These VOC can elevate viral transmission and evade the neutralizing antibody induced by vaccines, leading to reinfections. Understanding the impact of SARS-CoV-2 genomic mutation on viral pathogenesis and immune escape is crucial for assessing the threat of new variants to public health. This review focuses on the emergence and pathogenesis of VOC, with particular emphasis on their evasion of neutralizing antibodies. Furthermore, the memory B cell, CD4[SUP]+[/SUP], and CD8[SUP]+[/SUP] T cell memory induced by different COVID-19 vaccines or infections is discussed, along with how these cells recognize VOC. This review summarizes the current knowledge on adaptive immunology regarding SARS-CoV-2 infection and vaccines. Such knowledge may also be applied to vaccine design for other pathogens.
Keywords: COVID-19; Cellular immunity; Humoral immunity; SARS-CoV-2; Vaccines.
. 2023 Oct 19:S1673-8527(23)00211-4.
doi: 10.1016/j.jgg.2023.10.003. Online ahead of print. Humoral and cellular immunity against diverse SARS-CoV-2 variants
Changxu Chen[SUP] 1 [/SUP], Xin Wang[SUP] 1 [/SUP], Zeli Zhang[SUP] 2 [/SUP]
Affiliations
- PMID: 37865193
- DOI: 10.1016/j.jgg.2023.10.003
Since the outbreak of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in late 2019, the virus has rapidly spread worldwide. This has led to an unprecedented global pandemic, marked by millions of COVID-19 cases and a significant number of fatalities. Over a relatively short period, several different vaccine platforms were developed and deployed for use globally to curb the pandemic. However, the genome of SARS-CoV-2 continuously undergoes mutation and/or recombination, resulting in the emergence of several variants of concern (VOC). These VOC can elevate viral transmission and evade the neutralizing antibody induced by vaccines, leading to reinfections. Understanding the impact of SARS-CoV-2 genomic mutation on viral pathogenesis and immune escape is crucial for assessing the threat of new variants to public health. This review focuses on the emergence and pathogenesis of VOC, with particular emphasis on their evasion of neutralizing antibodies. Furthermore, the memory B cell, CD4[SUP]+[/SUP], and CD8[SUP]+[/SUP] T cell memory induced by different COVID-19 vaccines or infections is discussed, along with how these cells recognize VOC. This review summarizes the current knowledge on adaptive immunology regarding SARS-CoV-2 infection and vaccines. Such knowledge may also be applied to vaccine design for other pathogens.
Keywords: COVID-19; Cellular immunity; Humoral immunity; SARS-CoV-2; Vaccines.